Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
77.73
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
48
49
Next >
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
June 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
June 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Recent Stock Purchase June 2022
June 27, 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines.
Via
Talk Markets
Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues
June 27, 2022
Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the...
Via
Benzinga
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
June 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
June 27, 2022
More than four in 10 people in a recent survey knew of someone with long Covid.
Via
Investor's Business Daily
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
June 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
7 Biotech Stocks With Key Catalysts Coming in July
June 27, 2022
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.
Via
InvestorPlace
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
June 24, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Traders See Bumpy Road Ahead For Gilead Sciences
June 23, 2022
Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses.
Via
Benzinga
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
June 23, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
June 21, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
June 17, 2022
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic.
Via
Benzinga
Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions
June 14, 2022
Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture...
Via
Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
June 13, 2022
Via
Benzinga
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
June 13, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market...
Via
Benzinga
What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy
June 13, 2022
Via
Benzinga
There Are Some Serious Deals In The Market Right Now
June 11, 2022
Interested in buying high-quality dividend growth stocks on sale? Want to know my top five stocks for June 2022? Then you have to check out this video.
Via
Talk Markets
7 Great ETFs to Buy Now for Momentum in Q2
June 10, 2022
These seven ETFs to buy are among the best funds. YPS, BITQ, FMET, QQMG, DVY, XSD, and VHT can make excellent investments.
Via
InvestorPlace
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
June 08, 2022
Image provided by Pexels
Via
Benzinga
7 Oversold Stocks to Buy Right Now
June 08, 2022
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price.
Via
InvestorPlace
Gilead Joining the Global Access to Oncology Medicines Coalition
June 08, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
June 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
June 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)
June 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
June 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
June 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Michael Elliott Named to 2022 Empower Advocate Executive Role Model List.
June 03, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
June 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
June 2022 Stock Considerations
June 02, 2022
With the start of a new trading month, it is time, once again, to highlight some potential stock buys for June.
Via
Talk Markets
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.